Compare · CGC vs OBIO
CGC vs OBIO
Side-by-side comparison of Canopy Growth Corporation (CGC) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 8.4x OBIO ($339.0M).
- CGC has been more active in the news (11 items in the past 4 weeks vs 4 for OBIO).
- CGC has more recent analyst coverage (19 ratings vs 10 for OBIO).
- Company
- Canopy Growth Corporation
- Orchestra BioMed Holdings Inc.
- Price
- $0.74+2.91%
- $5.75+1.95%
- Market cap
- $2.86B
- $339.0M
- 1M return
- -
- -4.49%
- 1Y return
- -
- +55.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 4
- Recent ratings
- 19
- 10
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Director Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation
- Director Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability
- Director Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)
- Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum
- Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting
Latest OBIO
- Officer Sherman Darren sold $95,400 worth of shares (15,000 units at $6.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,119,402 units (SEC Form 4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
- Officer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,067,463 units (SEC Form 4) (tax withholding)
- Orchestra BioMed upgraded by BTIG Research with a new price target
- Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Hochman David P bought $47,900 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.94% to 1,070,746 units (SEC Form 4)
- Officer Sherman Darren sold $74,100 worth of shares (15,000 units at $4.94) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,134,402 units (SEC Form 4)